These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 30694073)
1. Low Risk of Adrenal Insufficiency After Use of Low- to Moderate-Potency Topical Corticosteroids for Children With Atopic Dermatitis. Davallow Ghajar L; Wood Heickman LK; Conaway M; Rogol AD Clin Pediatr (Phila); 2019 Apr; 58(4):406-412. PubMed ID: 30694073 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of Hypothalamic-Pituitary-Adrenal Axis Suppression following Cutaneous Use of Topical Corticosteroids in Children: A Meta-Analysis. Wood Heickman LK; Davallow Ghajar L; Conaway M; Rogol AD Horm Res Paediatr; 2018; 89(6):389-396. PubMed ID: 29898449 [TBL] [Abstract][Full Text] [Related]
3. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Ellison JA; Patel L; Ray DW; David TJ; Clayton PE Pediatrics; 2000 Apr; 105(4 Pt 1):794-9. PubMed ID: 10742322 [TBL] [Abstract][Full Text] [Related]
4. Adrenal function following topical steroid treatment in children with atopic dermatitis. Patel L; Clayton PE; Addison GM; Price DA; David TJ Br J Dermatol; 1995 Jun; 132(6):950-5. PubMed ID: 7662574 [TBL] [Abstract][Full Text] [Related]
5. Different potencies of topical corticosteroids for a better treatment strategy in children with atopic dermatitis (the Rotterdam Eczema study): protocol for an observational cohort study with an embedded randomised open-label controlled trial. van Halewijn KF; Bohnen AM; van den Berg PJ; Pasmans SGMA; Bindels PJE; Elshout G BMJ Open; 2019 Jun; 9(6):e027239. PubMed ID: 31221882 [TBL] [Abstract][Full Text] [Related]
7. Hydrocortisone butyrate 0.1% cream (proprietary lipid rich cream vehicle) does not significantly suppress hypothalamic-pituitary-adrenal axis and is effective in pediatric patients 3 months and older with extensive atopic dermatitis. Abramovits W; Oquendo M Skinmed; 2010; 8(3):150-4. PubMed ID: 21137620 [TBL] [Abstract][Full Text] [Related]
8. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation. Green C; Colquitt JL; Kirby J; Davidson P; Payne E Health Technol Assess; 2004 Nov; 8(47):iii,iv, 1-120. PubMed ID: 15527669 [TBL] [Abstract][Full Text] [Related]
9. Safety of topical corticosteroids in atopic eczema: an umbrella review. Axon E; Chalmers JR; Santer M; Ridd MJ; Lawton S; Langan SM; Grindlay DJC; Muller I; Roberts A; Ahmed A; Williams HC; Thomas KS BMJ Open; 2021 Jul; 11(7):e046476. PubMed ID: 34233978 [TBL] [Abstract][Full Text] [Related]
10. Intranasal corticosteroids and adrenal suppression. Bruni FM; De Luca G; Venturoli V; Boner AL Neuroimmunomodulation; 2009; 16(5):353-62. PubMed ID: 19571596 [TBL] [Abstract][Full Text] [Related]
11. Successful Treatment with Dupilumab in a Patient with Severe, Difficult to Treat Atopic Dermatitis: Beware of Symptomatic Adrenal Insufficiency due to Abrupt Discontinuation of Potent Topical Corticosteroids. Ariëns LFM; van der Schaft J; Stades AME; van de Woestijne AA; De Bruin-Weller MS Acta Derm Venereol; 2018 Jun; 98(6):601-602. PubMed ID: 29881868 [No Abstract] [Full Text] [Related]
12. Low basal serum cortisol in patients with severe atopic dermatitis: potent topical corticosteroids wrongfully accused. Haeck IM; Timmer-de Mik L; Lentjes EG; Buskens E; Hijnen DJ; Guikers C; Bruijnzeel-Koomen CA; de Bruin-Weller MS Br J Dermatol; 2007 May; 156(5):979-85. PubMed ID: 17298484 [TBL] [Abstract][Full Text] [Related]
13. [The use of topical corticosteroids in atopic dermatitis in children]. Cambazard F Ann Dermatol Venereol; 2005 Jan; 132 Spec No 1():1S64-7. PubMed ID: 15984295 [TBL] [Abstract][Full Text] [Related]
17. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled and nasal corticosteroids: is the early-morning serum adrenocorticotropic hormone (ACTH) a useful screening test? Zöllner EW; Lombard C; Galal U; Hough S; Irusen E; Weinberg E Pediatr Allergy Immunol; 2011 Sep; 22(6):614-20. PubMed ID: 21797928 [TBL] [Abstract][Full Text] [Related]
18. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis. Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989 [TBL] [Abstract][Full Text] [Related]
19. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016 [TBL] [Abstract][Full Text] [Related]
20. Risk of adrenal insufficiency following intra-articular or periarticular corticosteroid injections among children with chronic arthritis. Turmel-Roy J; Bédard MA; Millette M; Simonyan D; Proulx-Gauthier JP; Rousseau-Nepton I J Pediatr Endocrinol Metab; 2020 Aug; 33(10):1257-1263. PubMed ID: 32845867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]